UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect

Emily G Caggiano; Cullen M Taniguchi

doi:10.1007/s10555-023-10157-4

UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect

Cancer Metastasis Rev. 2024 Jan 9. doi: 10.1007/s10555-023-10157-4. Online ahead of print.

Authors

Emily G Caggiano^{1

2}, Cullen M Taniguchi^{3

4}

Affiliations

¹ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. EGCaggiano@mdanderson.org.
² The University of Texas MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. EGCaggiano@mdanderson.org.
³ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 38194152
DOI: 10.1007/s10555-023-10157-4

Abstract

Pancreatic cancer has an exaggerated dependence on mitochondrial metabolism, but methods to specifically target the mitochondria without off target effects in normal tissues that rely on these organelles is a significant challenge. The mitochondrial uncoupling protein 2 (UCP2) has potential as a cancer-specific drug target, and thus, we will review the known biology of UCP2 and discuss its potential role in the pathobiology and future therapy of pancreatic cancer.

Keywords: Metabolism; Mitochondria; Pancreatic cancer; Therapeutics; Uncoupling.

Publication types

Review